MetaVia and Syntekabio Collaborate on AI-Driven Drug Discovery

MetaVia Inc. has announced a research collaboration with Syntekabio to explore additional indications for DA-1241, its novel oral GPR119 agonist, announced in a press release. This partnership aims to leverage Syntekabio's DeepMatcher® AI platform to identify new disease targets and optimize the therapeutic profile of DA-1241.

The collaboration follows positive results from MetaVia's Phase 2a study of DA-1241, which showed favorable safety and tolerability, along with hepatoprotective and glucose-regulating effects in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). By utilizing Syntekabio's AI-driven compound-protein interaction prediction platform, the companies plan to conduct large-scale virtual screenings against over 1,700 validated protein targets to uncover new, high-potential indications.

MetaVia's DA-1241 has shown potential as a standalone or combination therapy for MASH and type 2 diabetes, promoting the release of key gut peptides that play roles in glucose and lipid metabolism. The collaboration is expected to accelerate the discovery process and maximize the therapeutic value of DA-1241, with initial insights anticipated later this year.